Genocea Biosciences

Cambridge, Mass.

Funding to date (in dollars): $23,000,000
Investors: SR One, Polaris Ventures

Using a technology developed at Harvard Medical School, Genocea can rapidly test experimental vaccines in a simulated version of the human immune system.

next slide previous slide